Navigation Links
Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Date:6/23/2009

KENILWORTH, N.J., June 23 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation (NYSE: SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Aug. 31, 2009, to shareholders of record at the close of business on August 7, 2009. As of March 31, 2009, there were 1,628,335,093 common shares outstanding.

The Board of Directors today also declared a quarterly dividend of $3.75 per share on the 2007 Mandatory Convertible Preferred Stock. Payment will be made on Aug. 17, 2009, to holders of record at the close of business on Aug. 3, 2009. There are currently 10 million shares of 2007 Mandatory Convertible Preferred Stock outstanding.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)... , ... February 15, 2017 , ... ... as President and Chief Commercial Officer with GenePeeks. Matt is a veteran ... GenePeeks is a computational genomics company focused on identifying inherited disease risk in ...
(Date:2/15/2017)... Februar 2017  Trianni, Inc. („TRIANNI") gab heute ... eine Lizenzvereinbarung über die Verwendung der The Trianni ... für die Entdeckung monoklonaler Antikörper. Die ... Gensegmentdesign aus, das Janssen den Zugang ... und das für die schelle Isolierung vollständig menschlicher ...
(Date:2/15/2017)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today ... quarter and full year ended December 31, 2016. ... Vanda as we continued to demonstrate strong growth ... for Fanapt," said Mihael H. Polymeropoulos, M.D., Vanda,s ... with important 2017 milestones underscores Vanda,s commitment to ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Biometrics Market 2017-2021" report to their offering. ... The global voice recognition biometrics ... 2017-2021. The report covers the present scenario and ... 2017-2021. To calculate the market size, the report considers the revenue ...
(Date:1/18/2017)... 18, 2017 MedNet Solutions , ... the entire spectrum of clinical research, is proud ... year for the organization in terms of corporate ... eClinical products and services. The company,s exceptional achievements ... of iMedNet ™ ...
Breaking Biology News(10 mins):